Alvotech, today welcomed the positive opinion of the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending the approval of Alvotech‘s high-concentration AVT02 (100 mg/mL), a proposed biosimilar to Humira® (adalimumab).  The CHMP’s positive opinion will

Approximately 530 participants will be enrolled in a comparative, confirmatory efficacy and safety study for AVT04 in plaque psoriasis, across Central and Eastern European countries.  AVT04 Pharmacokinetic (PK) comparability study in approximately 294 healthy volunteers is being conducted

Funds provide additional resources and runway for advancing the company's biosimilar pipeline. Reykjavik, Iceland June 24, 2021  – Alvotech Holdings SA today announced that it has entered into an amendment and restatement agreement with bondholders of its $300m convertible bond issued on December

Alvotech’s Proposed Interchangeable Product for High-Concentration Humira® Could Save U.S. Consumers and Taxpayers Billions Annually In May of 2021, Alvotech USA Inc. Sued to End AbbVie’s Wrongful Monopoly on Humira and Bring an Affordable Arthritis Treatment to the U.S.

Federal Court Filing Details AbbVie’s Continued Attempts to Squash Competition Over America’s Highest Grossing Prescription Drug Alvotech’s New Biosimilar Drug Would Provide Immediate Savings to Consumers Alvotech today filed a federal lawsuit seeking to end the monopoly that pharmaceutical giant

Alvotech strongly disputes AbbVie’s allegations of wrongdoing relating to AVT02, Alvotech’s proposed biosimilar to HUMIRA® (adalimumab). Alvotech will vigorously defend against these allegations. Notably, AbbVie waited over three years from the purported date of the alleged wrongdoing to file its

Alvotech has successfully completed a second round of its US$ 100 million private placement, for US$ 35 million. The first round which was completed in October 2020, amounted to US$ 65 million. As part of the first round Shinhan from Korea, Baxter Healthcare SA from the US and ATHOS (Strüngmann

Cipla Gulf and Alvotech today announced that they are expanding their partnership for the marketing and distribution of four biosimilar medicines in Australia and New Zealand. As part of this strategic alliance, Cipla Gulf will be responsible for commercialization of patented biosimilars of leading

Fuji Pharma will exclusively commercialize the medicines in Japan – discussions between the parties continue over additional biosimilar candidates Alvotech and Japanese pharmaceutical company Fuji Pharma (Tokyo Stock Exchange: 4554) announce that they have agreed on an extension on their exclusive

Through this partnership, a powerhouse has been created in one of the world’s largest biologics markets, designed to improve patient access to high quality biosimilars in China° Biosimilar candidates will be manufactured in a new Chinese biologic facility in Changchun Alvotech hf.